I
Inmaculada de la Torre
Researcher at Eli Lilly and Company
Publications - 72
Citations - 1989
Inmaculada de la Torre is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 17, co-authored 63 publications receiving 1275 citations. Previous affiliations of Inmaculada de la Torre include University College London & Hospital General Universitario Gregorio Marañón.
Papers
More filters
Journal ArticleDOI
Neutralizing monoclonal antibodies for treatment of COVID-19.
Peter C. Taylor,Andrew C. Adams,Matthew M. Hufford,Inmaculada de la Torre,Kevin L. Winthrop,Robert L. Gottlieb,Robert L. Gottlieb +6 more
TL;DR: In this article, neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical trials.
Journal ArticleDOI
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
Maxime Dougados,Désirée van der Heijde,Ying-Chou Chen,Maria Greenwald,E. Drescher,Jiajun Liu,Scott D. Beattie,Sarah Witt,Inmaculada de la Torre,Carol L. Gaich,Terence Rooney,Douglas E Schlichting,Stephanie de Bono,Paul Emery +13 more
TL;DR: In patients with rheumatoid arthritis and an inadequate response or intolerance to conventional synthetic DMARDs, baricitinib was associated with clinical improvement and inhibition of progression of radiographic joint damage.
Journal ArticleDOI
Association between anti–cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis
Francisco Javier López-Longo,Desamparados Oliver-Miñarro,Inmaculada de la Torre,Eugenia González‐Díaz de Rábago,Silvia Sánchez-Ramón,Margarita Rodríguez-Mahou,A. Paravisini,Indalecio Monteagudo,Carlos‐Manuel González,Marta García-Castro,María Dolores Casas,Luis Carreño +11 more
TL;DR: Patients with rheumatoid arthritis have an increased risk of cardiovascular disease that may not always be related to the presence of traditional cardiovascular risk factors, but patients who had positive anti-CCP antibodies experienced more frequent ischemic heart disease.
Journal ArticleDOI
Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis
Esperanza Naredo,Lara Valor,Inmaculada de la Torre,María Montoro,N. Bello,Julia Martínez-Barrio,Lina Martínez-Estupiñán,Juan Carlos Nieto,J.G. Ovalles-Bonilla,Diana Hernández-Flórez,Carlos M. González,Francisco Javier López-Longo,Indalecio Monteagudo,Luis Carreño +13 more
TL;DR: The results suggest that the presence of Doppler-detected synovitis may predict BT tapering failure in RA patients in sustained clinical remission.
Journal ArticleDOI
Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis
Bruno Fautrel,Rieke Alten,Bruce Kirkham,Inmaculada de la Torre,Frederick Durand,Jane Barry,Thorsten Holzkaemper,Walid D. Fakhouri,Peter C. Taylor +8 more
TL;DR: The timely and effective use of patient-reported outcomes (PROs) could encourage physicians to focus more on the impact of RA on patients and how patients are feeling, ultimately leading to a more patient-centered approach and improved patient care.